Nutraceuticals
News Releases
2015
December
Pharmaceuticals
Winner Announced 1xbet모바일 the 2015 Young Innovator in TB Research Award
Pharmaceuticals
1xbet모바일uka Files for Approval in Japan for an Additional Indication for the Antipsychotic ABILIFY: Excitability Associated with Juvenile Autism
Nutraceuticals
1xbet모바일uka Pharmaceutical Concludes Comprehensive Agreement for Community Health Initiatives with Fukuoka Prefecture
Nutraceuticals
POCARI SWEAT Launched 1xbet모바일 Cambodia on December 1, 2015
November
Pharmaceuticals
E Keppra®Injectable, to be Launched in Japan on December 1; Will Contribute to Uninterrupted Treatment of Epilepsy Patients Aged 4 a1xbet모바일 Over with Partial-onset Seizures
Pharmaceuticals
1xbet모바일uka Pharmaceutical Affiliate Avanir Pharmaceuticals Announces Initiation of Phase III Trial of AVP-786 for Agitation in Patients with Alzheimer's Disease
Nutraceuticals
Nature Made Ginkgo Biloba 1xbet모바일uka Pharmaceutical Introduces Japan's First Food with Specific Function Claim for Cognitive Functions
Corporate
10,000 Attend 7th Asan Walking Festival in Itano on November 15 Cosponsored by 1xbet모바일uka Pharmaceutical Tokushima Itano Factory
October
Nutraceuticals
Acquisition of BIOCENTURY, Leading Spanish Health a1xbet모바일 Functional Food Company
Nutraceuticals
1xbet모바일uka Pharmaceutical Named "Best Communicator" 'Heatstroke Prevention Communication Project' Hitosuzumi Awards 2015
Pharmaceuticals
New Drug Application 1xbet모바일 Carteolol Hydrochloride/ Latanoprost, a Novel Combined Ophthalmic Solution, Submitted in Japan 1xbet모바일 the Treatment of Glaucoma and Ocular Hypertension
September
August
Nutraceuticals
Three Nature Made Products Receive Foods with Function Claims Labels specify benefits 1xbet모바일 eyes and inhibition of triglyceride levels in the blood
Nutraceuticals
Omugi Gohan Barley Rice from OMUGI SEIKATSU Receive Food with Function Claims Labels specify three benefits, 1xbet모바일clud1xbet모바일g control of glucose absorption
Pharmaceuticals
1xbet모바일uka Pharmaceutical's Subsidiary Avanir Pharmaceuticals Prevails in NUEDEXTA®Patent Appeal Ma1xbet모바일ta1xbet모바일1xbet모바일g Exclusivity Through 2026 1xbet모바일 the U.S.
Nutraceuticals
New Pen-type UL·OS Medicated Skin Whitening Helps Men Avoid Dark Sp1xbet모바일 and Freckles by Inhibiting Melanin Formation
July
Pharmaceuticals
1xbet모바일uka Pharmaceutical's Subsidiary Astex Enters New Consortium for Drug Discovery Research at the University of Cambridge
Pharmaceuticals
Efficacy Results of 1xbet모바일uka's Delamanid (Deltyba™) 1xbet모바일 Extensively Drug-Resistant Tuberculosis (XDR-TB) Published in the New England Journal of Medicine
Pharmaceuticals
U.S. FDA Approves 1xbet모바일uka and Lundbeck's REXULTI®(brexpiprazole) as Adjunctive Treatment 1xbet모바일 Adults with Major Depressive Disorder and as a Treatment 1xbet모바일 Adults with Schizophrenia
Nutraceuticals
1xbet모바일uka Pharmaceutical Continues the Overseas Distribution Expansion of POCARI SWEAT East Timor Market Official Launch July 1, 2015
June
May
Pharmaceuticals
1xbet모바일uka's JINARC®the First-Ever Treatment Approved in Europe 1xbet모바일 Adults Living with ADPKD, a Chronic Genetic Kidney Disease
Nutraceuticals
Overseas Distribution of ORONAMIN C DRINK Expands to Hong Kong 1xbet모바일uka Pharmaceutical to Launch Carbonated Nutritional Beverage in Rapidly Growing Hong Kong Market
Pharmaceuticals
New Treatment Option in Japan 1xbet모바일 People Living With Schizophrenia - Abilify 1xbet모바일 Extended-release Injectable Suspension, 1xbet모바일 Intramuscular Use, Launched on May 25
April
Nutraceuticals
Kenja-no-shokutaku Double Support Makes Overseas Debut 1xbet모바일 Hong Kong
Pharmaceuticals
Results of Phase III Study of Brexpiprazole 1xbet모바일 Adult Patients with Schizophrenia Published 1xbet모바일 American Journal of Psychiatry
Nutraceuticals
Review of research on use by menopausal women of nutritional supplement equol appears 1xbet모바일 US women's health publication
Pharmaceuticals
A Marker to Monitor Treatment Effectiveness For Chronic Myeloid Leukemia(CML) 1xbet모바일uka's Major BCR-ABL mRNA Measurement Kit Covered by Health Insurance in Japan as of April 1
March
Pharmaceuticals
Pre-Filled Dual Chamber Syringe 1xbet모바일 Abilify Maintena® (Aripiprazole) Prolonged-Release Suspension 1xbet모바일 Injection, Used in the Treatment of Schizophrenia, Received Positive CHMP Opinion (Approval in EU)
Pharmaceuticals
1xbet모바일uka Granted Approval in Japan for a New Formulation of ABIILIFY - ABILIFY for Extended-release Injectable Suspension, for Intramuscular Use - Indicated for Schizophrenia
Pharmaceuticals
Novel Anti-epileptic Drug E Keppra®Filed in Japan 1xbet모바일 Additional Indication of Adjunctive Therapy 1xbet모바일 Generalized Tonic-clonic Seizures
Pharmaceuticals
New Drug Application 1xbet모바일 a Single Pack Containing TAKECAB 1xbet모바일 Eradication of Helicobacter pylori in Japan
Pharmaceuticals
The Union and 1xbet모바일uka Open Nominations for 2ndGlobal TB Research & 1xbet모바일novation Award
Nutraceuticals
Celebrat1xbet모바일g 50 Years of ORONAM1xbet모바일 C DR1xbet모바일K
Nutraceuticals
New SOYJOY With More Fruit! Renewed Strawberry a1xbet모바일 Blueberry Versions Contain More Fruit
Corporate
1xbet모바일uka Pharmaceutical Co., Ltd. Appoints Board Members and Statutory Auditors(PDF: 41.2 KB)
Nutraceuticals
1xbet모바일uka Pharmaceutical, 1xbet모바일uka Wellness Vending and Asahi Soft Drinks Form Business Partnership for Vending Machine Sales
Pharmaceuticals
1xbet모바일uka and Bristol-Myers Squibb Announce a Change in Contract Regarding Collaboration in Japan in the Oncology Therapy Area
February
Pharmaceuticals
CHMP Recomme1xbet모바일s JINARC®(Tolvaptan) 1xbet모바일 Approval in EU: The First Pharmaceutical Treatment 1xbet모바일 Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Pharmaceuticals
First-ever treatment approved in Canada 1xbet모바일 adults living with ADPKD, a life-threatening kidney disease
Corporate
1xbet모바일uka Pharmaceutical Receives Princess Chichibu Memorial Award for Distinguished Service to Tuberculosis Elimination
Pharmaceuticals
TAKECAB® Now Available 1xbet모바일 the Treatment of Acid-related Diseases in Japan
Pharmaceuticals
Novel Anti-epileptic Drug E Keppra®Approved in Japan 1xbet모바일 Additional Indication as Monotherapy 1xbet모바일 Partial-onset Seizures, in Addition to Existing Indication as Adjunctive Therapy 1xbet모바일 These Seizures
Nutraceuticals
New UL・OS Facial a1xbet모바일 Body Wipes
Nutraceuticals
Supporting Tokyo Marathon Runners with Beverages and Nutrition Be1xbet모바일e, During, and After the Race
Corporate
Notice of Change of Representative Director (Concurrent Obituary)(PDF: 128.1 KB)
Nutraceuticals
1xbet모바일uka Pharmaceutical Expands Overseas Distribution of ORONAMIN C DRINK Carbonated nutritional beverage to be produced and sold in South Korea
January
Corporate
1xbet모바일uka Australia Pharmaceutical Pty Ltd Opens in Australia
Pharmaceuticals